tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
PremiumThe FlyPsychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
26d ago
GH Research to Present Six-Month Safety and Efficacy Data on Inhaled GH001 in Depression at 2026 ACNP Meeting
Premium
Company Announcements
GH Research to Present Six-Month Safety and Efficacy Data on Inhaled GH001 in Depression at 2026 ACNP Meeting
26d ago
GH Research price target raised to $29 from $19 at Needham
Premium
The Fly
GH Research price target raised to $29 from $19 at Needham
28d ago
GH Research: FDA Lifts Clinical Hold on GH001, Clearing Path to Phase 3 and Supporting Buy Rating
PremiumRatingsGH Research: FDA Lifts Clinical Hold on GH001, Clearing Path to Phase 3 and Supporting Buy Rating
29d ago
GH Research to seek FDA alignment on Phase 3 program replicating Phase 2b design
Premium
The Fly
GH Research to seek FDA alignment on Phase 3 program replicating Phase 2b design
29d ago
GH Research says FDA lifts clinical hold on GH001
Premium
The Fly
GH Research says FDA lifts clinical hold on GH001
29d ago
Psychedelic: Atai Beckley, Cybin report quarterly earnings
PremiumThe FlyPsychedelic: Atai Beckley, Cybin report quarterly earnings
3M ago
GH Research: Proactive Regulatory Engagement and Strong Financial Positioning Support Buy Rating
Premium
Ratings
GH Research: Proactive Regulatory Engagement and Strong Financial Positioning Support Buy Rating
3M ago
Strategic Advancements and Financial Stability Drive Buy Rating for GH Research
Premium
Ratings
Strategic Advancements and Financial Stability Drive Buy Rating for GH Research
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100